The 4-1BB x PD-L1 bispecific antibody MCLA-145 has been developed with the specific aim of activating 4-1BB signalling in the tumour, where PD-L1 is expressed, as well as blocking immune-inhibitory signalling from the PD-1/PD-L1 axis. This evidence concerns the gene PDCD1 and neoplasm.